ABIVAX (ABVX) Q1 2025 earnings summary

Executive summary

• Reported a net loss of EUR 52.4M for Q1 2025, up 22% year-over-year, with operating loss at EUR 47.2M due to higher R&D expenses.

• Completed enrollment for Phase 3 ABTECT trials in ulcerative colitis in April 2025; results expected Q3 2025.

• Significant management changes, including new board appointments and executive transitions.

• Company focuses on developing obefazimod for chronic inflammatory diseases, with ongoing expansion of R&D pipeline.

• Expects to require additional funding to continue operations beyond Q4 2025.

Financial highlights

• Total operating income for Q1 2025 was EUR 1.0M, down 16% year-over-year.

• R&D expenses rose to EUR 39.3M, mainly due to clinical trial progress and increased staffing.

• Cash and equivalents at March 31, 2025, were EUR 103.6M, down from EUR 144.2M at year-end 2024.

• Net cash used in operations for Q1 2025 was EUR 33.3M; EUR 7.8M used for debt service.

• Net financial loss of EUR 5.2M, mainly from interest expenses, royalty certificates, and FX losses.

Outlook and guidance

• Cash runway expected to last until Q4 2025, covering key clinical milestones.

• Additional dilutive and non-dilutive funding will be needed to extend operations beyond Q4 2025.

• R&D spending projected to remain high due to ongoing phase 3 and phase 2b trials.

• Management highlights risks related to R&D, regulatory decisions, and funding availability.

• No major changes in risk factors or business outlook since the last annual report.